TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02118662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Expenditure during seated in an office chair
Description: You will first rest motionless in a chair for 20 minutes. You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Expenditure during seated in an office chair
Description: You will first rest motionless in a chair for 20 minutes. You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Expenditure during seated and typing
Description: You will complete this working conditions for 15 minutes. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Expenditure during seated and typing
Description: You will complete this working conditions for 15 minutes. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Expenditure during Treadmill walking work condition
Description: You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Expenditure during Treadmill walking work condition
Description: You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Expenditure during cycling work condition
Description: You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Expenditure during cycling work condition
Description: You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
Study: NCT01190046

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Resistance exercise training
Description: Lower extremity resistance exercise training 3x/wk
Study: NCT00426426

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioural Therapy
Description: 12 sessions with Cognitive-Behavioural Therapy (CBT), and waiting list will be over 12 weeks, and then allocated into Meta-Cognitive Therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioural Therapy
Description: 12 sessions with Cognitive-Behavioural Therapy (CBT), and waiting list will be over 12 weeks, and then allocated into Meta-Cognitive Therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meta-Cognitive Therapy
Description: 12 sessions with Meta-Cognitive Therapy (MCT), and waiting list will be over 12 weeks, and then allocated into Cognitive-Behavioural Therapy .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meta-Cognitive Therapy
Description: 12 sessions with Meta-Cognitive Therapy (MCT), and waiting list will be over 12 weeks, and then allocated into Cognitive-Behavioural Therapy .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waiting list

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waiting list

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting list
Study: NCT01023243

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Brochure: Care of the Feet for Those at Risk
Description: Patient education materials and key messages for care of the feet for those patients at risk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure: Care of the Feet for Those at Risk
Description: Patient education materials and key messages for care of the feet for those patients at risk

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality Survey: foot exam, tobacco and aspirin use
Description: NCQA Patient Survey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality Survey: foot exam, tobacco and aspirin use
Description: NCQA Patient Survey
Study: NCT03325543

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Verbal instruction and Vaginal palpation
Description: The experimental group will receive verbal instructions on the anatomy and function of PFMs associated with the use of body awareness techniques and vaginal palpation to learn the correct PFMs contraction. The control group will receive only verbal instructions on the anatomy and function of PFMs associated with the use of body awareness techniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal instruction and Vaginal palpation
Description: The experimental group will receive verbal instructions on the anatomy and function of PFMs associated with the use of body awareness techniques and vaginal palpation to learn the correct PFMs contraction. The control group will receive only verbal instructions on the anatomy and function of PFMs associated with the use of body awareness techniques.
Study: NCT00094328

Intervention type: DRUG
Group type: OTHER
Intervention: Bicalutamide
Description: oral

Intervention type: DRUG
Group type: OTHER
Intervention: Anastrozole
Description: oral
Study: NCT01876641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib + Cobimetinib, Decitabine
Study: NCT02283489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin adenovirus
Description: Specification: 1mL/division, 1.0×1012 virus particle (VP). ESD01 preparation: Thaw at room temperature, dilute with normal saline to required volume (no more than 2 mL).~Method of administration: Intratumor injection, once a week for 2 weeks, every 3 weeks for one cycle. Select only one target lesion even when lesions are present. The target lesion is the largest and easiest to inject. This will be fixed during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin adenovirus
Description: Specification: 1mL/division, 1.0×1012 virus particle (VP). ESD01 preparation: Thaw at room temperature, dilute with normal saline to required volume (no more than 2 mL).~Method of administration: Intratumor injection, once a week for 2 weeks, every 3 weeks for one cycle. Select only one target lesion even when lesions are present. The target lesion is the largest and easiest to inject. This will be fixed during the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Specification: 2ml: 10mg. Usage: 25mg/m2, days 1 to 3, according to instruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Specification: 2ml: 10mg. Usage: 25mg/m2, days 1 to 3, according to instruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Specification: 2ml: 10mg. Usage: 25mg/m2, days 1 to 3, according to instruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: Specification: 5ml: 30mg. Usage: 160mg/m2 intravenously on day 1, according to instruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: Specification: 5ml: 30mg. Usage: 160mg/m2 intravenously on day 1, according to instruction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: Specification: 5ml: 30mg. Usage: 160mg/m2 intravenously on day 1, according to instruction.
Study: NCT02821624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38 (CDK 4/6 Inhibitor)
Description: CDK 4/6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38 (CDK 4/6 Inhibitor)
Description: CDK 4/6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38 (CDK 4/6 Inhibitor)
Description: CDK 4/6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38 (CDK 4/6 Inhibitor)
Description: CDK 4/6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38 (CDK 4/6 Inhibitor)
Description: CDK 4/6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38 (CDK 4/6 Inhibitor)
Description: CDK 4/6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38 (CDK 4/6 Inhibitor)
Description: CDK 4/6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38 (CDK 4/6 Inhibitor)
Description: CDK 4/6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38 (CDK 4/6 Inhibitor)
Description: CDK 4/6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38 (CDK 4/6 Inhibitor)
Description: CDK 4/6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38 (CDK 4/6 Inhibitor)
Description: CDK 4/6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1T38 (CDK 4/6 Inhibitor)
Description: CDK 4/6 Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02402296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: β-1,3/1,6-D-glucan
Description: 15 patients (in group II) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of β-1,3/1,6-D-glucan oral supplementation for 40 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 patients (in group I) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of placebo capsules oral supplementation for 40 days.
Study: NCT00722579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRESILLION cobalt chromium stent
Description: PTCA with bare-metal stent
Study: NCT02173730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS
Description: BIBR 1048 MS capsule 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS
Description: BIBR 1048 MS capsule 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole tablet 40 mg
Study: NCT00817375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI treated group
Description: Antidepressant administration of SSRI class for 6 weeks under therapeutic dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-SSRI treated group
Description: Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
Study: NCT01202487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LET - Lidocaine Epinephrine Tetracaine
Description: One time application of 3 cc of Lidocaine Epinephrine Tetracaine Solution at least 45 minutes prior to laceration repair

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LET - Lidocaine Epinephrine Tetracaine
Description: One time application of 3 cc of Lidocaine Epinephrine Tetracaine Solution at least 45 minutes prior to laceration repair
Study: NCT01874145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GA 20 mg/mL
Description: Glatiramer acetate (GA) 20 mg/mL subcutaneous (SC) injection, the commercial product, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA 40 mg/mL
Description: Glatiramer acetate (GA) 40 mg/mL subcutaneous (SC) injection, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
Study: NCT03889613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prospective follow-up with videocapsule
Description: prospective follow-up with videocapsule
Study: NCT04631705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DZIF-10c
Description: Inhaled administration of the human monoclonal antibody DZIF-10c

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DZIF-10c
Description: Inhaled administration of the human monoclonal antibody DZIF-10c

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DZIF-10c
Description: Inhaled administration of the human monoclonal antibody DZIF-10c

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DZIF-10c
Description: Inhaled administration of the human monoclonal antibody DZIF-10c

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DZIF-10c
Description: Inhaled administration of the human monoclonal antibody DZIF-10c

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DZIF-10c
Description: Inhaled administration of the human monoclonal antibody DZIF-10c

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DZIF-10c
Description: Inhaled administration of the human monoclonal antibody DZIF-10c

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DZIF-10c
Description: Intravenous administration of the human monoclonal antibody DZIF-10c

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inhalation of DZIF-10c diluent as placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of sterile normal saline (NaCl 0.9%) as placebo
Study: NCT04179981

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive airway pressure
Description: Positive airway pressure therapy. OVS patients randomized to PAP therapy arm will be titrated to optimal PAP therapy per standard protocol and assigned to use PAP therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Conservative care (control arm)
Description: Eligible OVS patients will receive conservative care/usual care with education about sleep apnea and sleep hygiene via handouts and video instructions. This is the control arm.
Study: NCT03557086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advance Care Planning Video Decision Support Tool
Description: Advance care planning video intervention as previously described

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Verbal Narrative
Description: Verbal description of end of life care options
Study: NCT06040996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving Parenting Skills adult ADHD (IPSA)
Description: Parent training program for parents with ADHD. The program combines structured group-based skills training with individualized support, including occupational therapist support to help parents improve their own prerequisites for bringing about change and facilitate use of the introduced parenting skills.

Intervention type: OTHER
Group type: OTHER
Intervention: Continued Routine Services
Description: Continued Routine Services while waiting for IPSA (offered approximately 6 months later)
Study: NCT00600379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality system (CAREN™ Integrated Reality System; MOTEK BV, Netherlands).
Description: Training 2/w for 9 weeks (total 18 sessions).
Study: NCT00114361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 1200 mg a day, 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alpha 2a
Description: 180 µg per week, 48 weeks
Study: NCT03931447

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-72537634
Description: Participants in Cohort 1 and 3 will receive Dose 1 and participants in Cohort 2 and 4 will receive Dose 2 of JNJ-72537634 as oral capsule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-72537634
Description: Participants in Cohort 1 and 3 will receive Dose 1 and participants in Cohort 2 and 4 will receive Dose 2 of JNJ-72537634 as oral capsule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-72537634
Description: Participants in Cohort 1 and 3 will receive Dose 1 and participants in Cohort 2 and 4 will receive Dose 2 of JNJ-72537634 as oral capsule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-72537634
Description: Participants in Cohort 1 and 3 will receive Dose 1 and participants in Cohort 2 and 4 will receive Dose 2 of JNJ-72537634 as oral capsule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as oral capsule in all cohorts.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as oral capsule in all cohorts.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as oral capsule in all cohorts.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as oral capsule in all cohorts.
Study: NCT00925535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lersivirine
Description: 1000 mg once daily for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifabutin
Description: 300 mg once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: 1000 mg once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: 300 mg once daily for 10 days
Study: NCT01653080

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced MRI
Description: Studies will be performed on standard clinical MR Systems which are available on Campus. With the proposed imaging technique, we are able to acquire a 3D volume covering the orbit with a temporal resolution of approximately 15s. The affected eye will be immobilized to reduce motion artifacts. A routinely used MR contrast agent will be administered in a dose of 0.1mmol/kg bodyweight.
Study: NCT04534114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesomersen sodium (BAY2976217)
Description: Study intervention will be injected subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesomersen sodium (BAY2976217)
Description: Study intervention will be injected subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesomersen sodium (BAY2976217)
Description: Study intervention will be injected subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to BAY2976217 will be injected subcutaneously.
Study: NCT01980615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled BGF (PT010) Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled BGF (PT010) Dose 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled BGF (PT010) Dose 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled BGF (PT010) Dose 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled BGF (PT010) Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled BGF (PT010) Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled BGF (PT010) Dose 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled BGF (PT010) Dose 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled BGF (PT010) Dose 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled BGF (PT010) Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled BGF (PT010) Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled BGF (PT010) Dose 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled BGF (PT010) Dose 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled BGF (PT010) Dose 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled BGF (PT010) Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled GFF (PT003)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled GFF (PT003)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled GFF (PT003)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled GFF (PT003)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled GFF (PT003)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Symbicort Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Symbicort Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Symbicort Dose 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Symbicort Dose 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Symbicort Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Symbicort Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Symbicort Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Symbicort Dose 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Symbicort Dose 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Symbicort Dose 2